Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Gilliland

Showing results (171-180 of 182) with videos related to

Pageof 19
Sort By:
Blood|August 6, 2005
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemiaRoss L Levine, Marc Loriaux, Brian J P Huntly, et al.
Cancer Discovery|August 9, 2014
Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinomaAlexander Stoeck, Serguei Lejnine, Andrew Truong, et al.
Blood|May 8, 2009
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesOmar Abdel-Wahab, Ann Mullally, Cyrus Hedvat, et al.
Cancer Cell|July 18, 2006
Activating alleles of JAK3 in acute megakaryoblastic leukemiaDenise K Walters, Thomas Mercher, Ting-Lei Gu, et al.
Cancer Cell|June 5, 2003
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative diseaseJan Cools, Elizabeth H Stover, Christina L Boulton, et al.
The New England Journal of Medicine|March 28, 2003
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndromeJan Cools, Daniel J DeAngelo, Jason Gotlib, et al.
Cancer Cell|April 20, 2005
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisRoss L Levine, Martha Wadleigh, Jan Cools, et al.
Plos One|October 8, 2014
MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosisRobert N Booher, Harold Hatch, Brian M Dolinski, et al.
Nature|October 23, 2009
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1David A Barbie, Pablo Tamayo, Jesse S Boehm, et al.
Nature Chemical Biology|October 29, 2013
Niche-based screening identifies small-molecule inhibitors of leukemia stem cellsKimberly A Hartwell, Peter G Miller, Siddhartha Mukherjee, et al.
Pageof 19

Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
Blood|August 6, 2005
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemiaRoss L Levine, Marc Loriaux, Brian J P Huntly, et al.
Cancer Discovery|August 9, 2014
Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinomaAlexander Stoeck, Serguei Lejnine, Andrew Truong, et al.
Blood|May 8, 2009
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesOmar Abdel-Wahab, Ann Mullally, Cyrus Hedvat, et al.
Cancer Cell|July 18, 2006
Activating alleles of JAK3 in acute megakaryoblastic leukemiaDenise K Walters, Thomas Mercher, Ting-Lei Gu, et al.
Cancer Cell|June 5, 2003
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative diseaseJan Cools, Elizabeth H Stover, Christina L Boulton, et al.
The New England Journal of Medicine|March 28, 2003
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndromeJan Cools, Daniel J DeAngelo, Jason Gotlib, et al.
Cancer Cell|April 20, 2005
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisRoss L Levine, Martha Wadleigh, Jan Cools, et al.
Plos One|October 8, 2014
MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosisRobert N Booher, Harold Hatch, Brian M Dolinski, et al.
Nature|October 23, 2009
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1David A Barbie, Pablo Tamayo, Jesse S Boehm, et al.
Nature Chemical Biology|October 29, 2013
Niche-based screening identifies small-molecule inhibitors of leukemia stem cellsKimberly A Hartwell, Peter G Miller, Siddhartha Mukherjee, et al.
Pageof 19